Tema Etfs LLC Invests $813,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Tema Etfs LLC bought a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,215 shares of the biotechnology company’s stock, valued at approximately $813,000.

A number of other institutional investors have also recently made changes to their positions in the business. Blue Trust Inc. increased its stake in shares of Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock worth $29,000 after buying an additional 309 shares during the period. YANKCOM Partnership purchased a new stake in shares of Viking Therapeutics in the fourth quarter valued at about $33,000. FIL Ltd lifted its position in Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 648 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of Viking Therapeutics by 170.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 851 shares during the period. Finally, Kapitalo Investimentos Ltda purchased a new stake in shares of Viking Therapeutics in the fourth quarter valued at about $63,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Trading Up 3.8%

Viking Therapeutics stock opened at $28.43 on Friday. The company has a market capitalization of $3.19 billion, a P/E ratio of -28.43 and a beta of 0.75. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.73. The firm’s fifty day simple moving average is $26.15 and its 200-day simple moving average is $36.36.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup started coverage on shares of Viking Therapeutics in a research report on Friday, February 7th. They set a “neutral” rating and a $38.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Thursday, April 24th. Truist Financial reissued a “buy” rating and issued a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. Morgan Stanley reduced their target price on Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. Finally, Piper Sandler decreased their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.15.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the company’s stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the purchase, the director now owns 1,240 shares in the company, valued at $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.10% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.